FDA Calls for Public Comments Regarding International Classification Of Cannabis

MARYLAND: The US Food and Drug Administration is seeking public comments specific to whether changes ought to be recommended regarding the international classification of cannabis as a controlled substance. Members of the public have until October 31, 2018 to submit their comments to the FDA for consideration.

fda-logo

The FDA says that the comments “will be considered in preparing a response from the United States to the World Health Organization regarding the abuse liability and diversion” of marijuana and certain other substances.

In April, in response to a similar FDA request, NORML collected and hand-delivered over 10,000 comments to the agency calling on it to recommend a lifting of international restrictions criminalizing the plant.

In NORML’s latest comments to the FDA, it opines that “cannabis be removed from the international drug conventions so that nations that wish to do so may further expand their regulations governing cannabis’ use, possession, production, and dispensing for either recreational or medical use.”

SUBMIT A COMMENT


For more information, contact Justin Strekal, NORML Political Director, at (202) 483-5500.

How Rescheduling Could Have Changed Cannabis Marketing

By Celeste Miranda

COLORADO: The DEA schedules substances, chemicals and drugs into 5 classified categories. Between Schedule 1 to 5 the level of potential for abuse gets more likely as the number goes down, so Schedule 1 is listed as the most dangerous for the public and Schedule 5 the least.  A Schedule 1 drug has been identified by the government as a substance with no potential for medicinal use and a high potential for abuse. Aside from cannabis schedule I also includes ecstasy, peyote and heroin. This DEA scheduling makes cannabis highly illegal to carry without the proper permits and also bars any scientific research on the medicinal value of the plant.

For the last couple of months the DEA has been pushing back their announcement on rescheduling cannabis to Schedule II. Last week they announced that cannabis would remain Schedule 1 which has equally angered and saddened the cannabis community. Not only does this continue the war on patients that has been raging across the country, but the negative effects of federal restrictions are more severe than cocaine and oxycodone blanket every aspect of the plant from research to marketing.

Real scientific research feeds an educational marketing platform.  One of the biggest problems that cannabis has faced is a lack of scientific research. Being classified as Schedule I, any relevant scientific research outside of cannabis that comes from a sterile government garden and is carried out by only a few government approved scientists. The ability to prove that the plant has medicinal value and move past a Schedule I classification is being blocked by that same classification. If and when the feds finally reschedule cannabis we will be able to partake in valuable research that will only fuel marketing efforts. If all of the research analysts that have been dying to get well grown hydroponic, outdoor and aeroponic cannabis into their laboratories were finally able to, there would be a bounty of research to fuel new content that will bring in an entirely untapped target demographic. Educational based platforms are the only way to ensure that no target client is left out of a marketing campaign and currently the cannabis education is mostly just conjecture or experiential. With real, hard data proving the medicinal value of cannabis the entire industry could change.